Publications

Filter Publications By:

Encorafenib / Cancer

07/17/2013

World Congress of Melanoma

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid Tumors

R. Kefford, et al.

Encorafenib / Cancer

07/13/2013

International Melanoma Conference

Initial Results from an Open-label, Dose-escalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600-mutant Advanced Melanoma

R. Dummer, et al.

Binimetinib / Cancer

07/13/2013

International Melanoma Conference

Initial Results from an Open-label, Dose-escalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600-mutant Advanced Melanoma

R. Dummer, et al.

Encorafenib / Cancer

07/12/2013

International Melanoma Conference

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination with the Oral MEK1/2 Inhibitor MEK162 in BRAF V600-Dependent Advanced Solid Tumors

R. Kefford, et al.

Encorafenib / Cancer

07/12/2013

International Melanoma Conference

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination with the Oral MEK1/2 Inhibitor MEK162 in BRAF V600-Dependent Advanced Solid Tumors

R. Kefford, et al.

ASLAN001 / Cancer

06/17/2013

Heterocyclic Compounds GRC

Process Research and Development of the Tyrosine Kinase Inhibitor Varlitinib Tosylate (ARRY-543 Ditosylate)

D. D. Hennings, et al.

Filanesib / Multiple Myeloma

06/17/2013

European Hematology Association Annual Congress

ALPHA 1-ACID GLYCOPROTEIN (AAG) IS A POTENTIAL PATIENT SELECTION MARKER FOR CLINICAL ACTIVITY OF ARRY-520 IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM)

B.J. Tunquist, et al.

Filanesib / Multiple Myeloma

06/12/2013

European Hematology Association Annual Congress

Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

J.J. Shah, MD, et al.

Selumetinib / Cancer

06/08/2013

Children’s Tumor Foundation’s Neurofibromatosis Conference

A Phase I Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib) in Children and Young Adults with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibromas (PN)

B. Widemann, MD, et al.

Danoprevir / Hepatitis C

06/05/2013

Journal of Medicinal Chemistry

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

Y. Jiang, et al.